Delving into the Latest Updates on Anfibatide with Synapse

This is a phase 1, dose-escalation, and multidose study, aiming to investigate the tolerability, safety and pharmacokinetics of Anfibatate in healthy subjects. The study is divided into 2 intravenous single groups and 3 continuous administration groups. The dose of Anfibatate from 5 IU/60kg to 7 IU/60kg in intravenous single groups. The dose of Anfibatate from 0.002 IU/kg/h, 0.004 IU/kg/h to 0.008 IU/kg/h in continuous administration groups.

Start Date01 Sep 2020

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

NCT04021173 / Unknown statusPhase 2

A Multicenter, Randomized, Double-blind, Placebo-parallel, Phase II Clinical Trial of the Efficacy and Safety of Anfibatide in Treating Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)

This is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II clinical study. It is planned to recruit 74 patients with acquired thrombotic thrombocytopenic purpura (TTP). To evaluate the efficacy and safety of Anfibatide as an adjuvant therapy for plasma exchange in patients with acquired TTP.

Start Date01 Jul 2019

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

CTR20180962 / RecruitingPhase 1

注射用抗血小板溶栓素Ⅰ期临床人体耐受性与药代动力学研究

[Translation] Phase I clinical study on human tolerance and pharmacokinetics of antiplatelet thrombolytics for injection

1.考察健康受试者静脉推注本品单次用药和连续给药的安全性及耐受性；2.考察药效学特征指标，血小板聚集抑制率；3.初步考察心脏安全指标，为将来试验对患者心脏安全评估提供指导；4.探索5IU和7IU单次给药可以达到的血小板聚集抑制率及5IU和7IU连续给药可以维持的血小板聚集抑制率。

[Translation]

1. To investigate the safety and tolerability of single and continuous intravenous injection of this product in healthy subjects; 2. To investigate the pharmacodynamic characteristic indicators and platelet aggregation inhibition rate; 3. To preliminarily investigate cardiac safety indicators to provide guidance for future trials on cardiac safety assessment of patients; 4. To explore the platelet aggregation inhibition rate that can be achieved by single administration of 5IU and 7IU and the platelet aggregation inhibition rate that can be maintained by continuous administration of 5IU and 7IU.

Start Date28 Jan 2019

Sponsor / Collaborator

Zhaoke Pharmaceutical (Hefei) Co., Ltd.

100 Clinical Results associated with Anfibatide

Login to view more data

100 Translational Medicine associated with Anfibatide

Login to view more data

100 Patents (Medical) associated with Anfibatide

Login to view more data

50

Literatures (Medical) associated with Anfibatide

28 May 2024·Blood Advances

Targeting neutrophil extracellular trap accumulation under flow in patients with immune-mediated thrombotic thrombocytopenic purpura

Article

Author: Gralnek, Sarah H. ; Zheng, Liang ; Zheng, X. Long ; Bignotti, Antonia ; Zhang, Quan ; Sosnovske, Dennis ; Ye, Zhan ; Yada, Noritaka ; Hogan, Keenan

AbstractNeutrophil NETosis is a unique form of cell death, characterized by the release of decondensed chromatin and antimicrobial contents to the extracellular space, which is involved in inflammation and thrombosis. However, the role of NETosis in the pathogenesis of immune-mediated thrombotic thrombocytopenic purpura (iTTP) and how a targeted therapy affects the accumulation of neutrophil extracellular traps (NETs) under flow remain unknown. Flow cytometry demonstrated that the percentage of neutrophils undergoing NETosis in whole blood from patients with iTTP on admission was significantly increased, with a concurrent decrease in the capacity of inducible NETosis by shigatoxin. After therapy, the percentage of H3Cit+MPO+ neutrophils was significantly reduced, with an improvement in inducible NETosis in these patients. Additionally, little to no NET and thrombus formation was detected underflow in the whole blood from patients with iTTP when platelet counts were very low, but the NET and thrombus formation was dramatically increased following therapy when platelet counts rose to ≥50 × 109/L or were restored to normal with donor platelets. Similarly, there was no thrombus or NET accumulation under flow in the whole blood from vwf-/- mice, but NET accumulation was significantly higher in Adamts13-/- mice than in wild-type mice. Finally, recombinant ADAMTS13 or caplacizumab (or anfibatide) prevented NET and thrombus formation under flow in whole blood from patients with iTTP or from Adamts13-/- mice. These results indicate that neutrophil NETosis and NET formation depend on platelets and von Willebrand factor (VWF) in iTTP, and a targeted therapy such as recombinant ADAMTS13 or caplacizumab may prevent NET and thrombus formation under flow in iTTP.

01 Jan 2023·Computational and Structural Biotechnology Journal

Assembly of an active microbial consortium by engineering compatible combinations containing foreign and native biocontrol bacteria of kiwifruit

Article

Author: Li, Li ; Zhong, Caihong ; Zhou, Longteng ; Lin, Long ; Wang, Bozhen ; Qian, Guoliang ; Wang, Limin ; Shao, Xiaolong ; Tao, Min ; Wu, Qianhua

Assembling functional bacterial biocontrol consortia is expected to expand the scope and efficiency of biocontrol agents. Generally, bacterial interspecies interactions lead to incompatibility events, as bacteria can produce antibacterial compounds and/or assemble contact-dependent killing (CDK) devices. Here, we aimed to assemble a bacterial consortium comprising Lysobacter enzymogenes OH11 and Bacillus safensis ZK-1 for the synergistic control of bacterial and fungal diseases of kiwifruit. ZK-1, a native kiwifruit biocontrol bacterium, is effective against Pseudomonas syringae pv. actinidiae (Psa) that causes bacterial kiwifruit canker, but has weak antifungal activity. OH11 is a foreign kiwifruit biocontrol agent with strong antifungal activity. While OH11 was unable to produce anti-Gram-negative metabolites, this strain could utilize type IV secretion system as an antibacterial CDK weapon. We first observed that OH11 could inhibit growth of ZK-1 by generating diffusible anti-Gram-positive antibiotic WAP-8294A2, whereas ZK-1 failed to generate diffusible antibacterial compound to inhibit growth of OH11. To disrupt this interspecies incompatibility, we generated a transgenic OH11-derived strain, OH11W, by deleting the WAP-8294A2 biosynthetic gene and found that OH11W did not kill ZK-1. We further observed that when OH11W and ZK-1 were co-inoculated on agar plates, no CDK effect was observed between them, whereas co-culture of OH11W or ZK-1 with Psa on agar plates resulted in Psa killing, suggesting L. enzymogenes and B. safensis assemble antibacterial CDK weapons against bacterial pathogens, and these CDK weapons did not affect the compatibility between OH11W and ZK-1. Based on these findings, we assembled an OH11W/ZK-1 dependent consortium that was shown to be functional in controlling bacterial canker and several representative fungal diseases of kiwifruit.

01 Jul 2022·European Journal of PharmacologyQ3 · MEDICINE

Anfibatide alleviates inflammation and apoptosis via inhibiting NF-kappaB/NLRP3 axis in ischemic stroke

Q3 · MEDICINE

Article

Author: Li, Rui ; Ma, Zheng ; Gong, Peng ; Dai, Xiang-Rong ; Luo, Sheng-Yong ; Jia, Hui-Yu ; Li, Xin-Wei ; Si, Min ; Li, Xiao-Yi

Recent evidence suggests that Nod-like receptor protein-3 (NLRP3) inflammasome is a key mediator of inflammatory response and can induce the activation of apoptosis signaling pathways in ischemic stroke. In this research, we assessed the effects of anfibatide (ANF) on inflammatory and apoptosis in cerebral ischemic injury and the potential mechanisms. Middle cerebral artery occlusion (MCAO) model was established on male Sprague-Dawley rats to induce cerebral ischemia/reperfusion (I/R) injury in vivo. Primary cortical neurons (PCN) cells were exposed to oxygen-glucose deprivation and reintroduction (OGD/R) to mimic cerebral I/R injury in vitro. The results showed that ANF markedly alleviated infarct volume, neurological deficit and neurobehavioral impairment in MCAO/R rats, enhanced cell viability and decreased LDH release in PCN after OGD/R. The number of TUNEL-positive cells, Bax, cleaved-caspase-3, p-IκBα, p-p65, NLRP3, ASC, cleaved caspase-1, IL-β and IL-18 proteins expression were significantly upregulated in the cortex of MCAO/R rats and PCN exposed to OGD/R, NLRP3 and caspase-1 mRNA levels were also evidently elevated. Bcl-2 protein expression significantly decreased in the cortex of MCAO/R rats. Treatment with ANF obviously inhibited the expression of p-IκBα, p-p65, NLRP3, ASC, cleaved caspase-1, Bax and cleaved-caspase-3, promoted the expression of Bcl-2, then decreased the TUNEL-positive cell number and the level of inflammatory cytokines (IL-β and IL-18) in cerebral ischemia reperfusion in vito and in vitro. Our findings suggest that ANF exerts effects of alleviating inflammation and apoptosis through inhibiting NF-kappaB/NLRP3 axis. ANF is a potential candidate for treating cerebral I/R injury.

100 Deals associated with Anfibatide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15094

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Coronary Syndrome	Phase 2	CN	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	14 Jan 2016
Thrombosis	Phase 1	HK	Lee's Pharmaceutical Holdings Ltd.	15 Nov 2013
Thrombosis	Phase 1	CA	St. Michael's Hospital	15 Nov 2013
Thrombosis	Phase 1	CN	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	15 Nov 2013
Thrombotic Thrombocytopenic Purpura, Acquired	Discovery	CN	Lee's Pharmaceutical Holdings Ltd.	01 Jul 2019
ST Elevation Myocardial Infarction	Discovery	CN	Lee's Pharmaceutical Holdings Ltd.	01 Aug 2015
Non-St Elevated Myocardial Infarction	Discovery	CN	Lee's Pharmaceutical Holdings Ltd.	01 Jul 2012
Blood Coagulation Disorders	Discovery	-	Lee's Pharmaceutical Holdings Ltd.	01 Sep 2010
Coronary Disease	Discovery	-	Lee's Pharmaceutical Holdings Ltd.	01 Sep 2010